ArticleNature cardiovascular research2024
Cytotoxic T cells drive doxorubicin-induced cardiac fibrosis and systolic dysfunction.
Abstract read
In one paragraph
Article in Nature cardiovascular research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Integrated single-cell RNA sequencing and mendelian randomization analysis identifies causal immune-related driver genes in the heart failure inflammatory microenvironment.Cardiovascular diagnosis and therapy · 2026Article
- Metabolic Reprogramming-Driven Cardiovascular Immune Damage: From Glyco-Lipotoxicity and Epigenetic Memory to Multidimensional Cross-Organ Communication Networks.International journal of molecular sciences · 2026Review
- Cardiotoxicity induced by multiple myeloma therapies: mechanistic convergence across proteasome inhibitors, CAR-T, and bispecific antibodies.Blood cancer journal · 2026Review
- Sushi, von Willebrand Factor Type A, EGF and Pentraxin Domain-Containing Protein 1: A Novel Fibroblast-Derived Circulating Biomarker Reflecting Cardiac Fibrosis.Journal of the American Heart Association · 2026Article
- CD74 deficiency protects against doxorubicin cardiotoxicity through RRM2-mediated regulation of ferroptosis.Acta pharmaceutica Sinica. B · 2026Article
- T cell-derived IFNγ instructs ECM crosslinking by cardiac fibroblasts through LOXL3 in experimental cardiometabolic HFpEF.bioRxiv : the preprint server for biology · 2026Article
- Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- CD160Cellular & molecular immunology · 2026Article
- Plasma exosomal hsa-miR-339-5p is associated with NOD-like receptor family CARD domain-containing 5 in heart failure with reduced ejection fraction.Scientific reports · 2026Article
- Caught in the crossfire: cardiac complications of cancer therapy.The Journal of clinical investigation · 2026Review
- Integrating Microarray Analysis, Machine Learning, and Molecular Docking to Explore the Mechanism of Doxorubicin-induced Cardiotoxicity.Current medicinal chemistry · 2026Article
- T cells in cardiovascular disease: solved and unsolved mysteries.Science China. Life sciences · 2026Review
- The mechanisms and therapeutic advances of interactions between breast cancer and cardiovascular diseases.Frontiers in pharmacology · 2026Review
- Integrating mechanical cues inFrontiers in immunology · 2026Review
- Integration of cAMP and TRPV4 Signaling to Optimize Collagen Remodeling for Management of Fibrosis.Cells · 2025Review
- Targeting LTBP2 Reveals a Novel Anti-Cardiac Remodeling Mechanism of Finerenone Against Doxorubicin-Induced Cardiotoxicity.Biomolecules · 2025Article
- Chemotherapy-induced cardiotoxicity in breast cancer: mechanisms, diagnostic advances, and emerging protective strategies.American journal of physiology. Heart and circulatory physiology · 2025Review
- Alteration of cardiac energetics and mitochondrial function in doxorubicin‑induced cardiotoxicity: Molecular mechanism and prospective implications (Review).International journal of molecular medicine · 2025Review
- A novel feedback loop: CELF1/circ-CELF1/BRPF3/KAT7 in cardiac fibrosis.Acta pharmaceutica Sinica. B · 2025Article
- Temporal analysis of doxorubicin-induced cardiac toxicity and hypertrophy.NPJ systems biology and applications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Abraham L BayerDepartment of Immunology, Tufts University, Boston, MA, USA.
Maria A ZambranoDepartment of Immunology, Tufts University, Boston, MA, USA.
Sasha SmolgovskyDepartment of Immunology, Tufts University, Boston, MA, USA.
Zachary L RobbeDepartment of Immunology, Tufts University, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5154-0742
Abul ArizaCardioVascular Institute, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2389-9920
Kuljeet KaurDepartment of Immunology, Tufts University, Boston, MA, USA.
Machlan SawdenDepartment of Immunology, Tufts University, Boston, MA, USA.
Anne AveryDepartment of Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Science, Colorado State University, Fort Collins, CO, USA.
Cheryl LondonDepartment of Immunology, Tufts University, Boston, MA, USA.
Aarti AsnaniCardioVascular Institute, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Pilar AlcaideDepartment of Immunology, Tufts University, Boston, MA, USA. pilar.alcaide@tufts.edu.ORCID http://orcid.org/0000-0003-3013-3982
Funding
Hemopexin as an Early Biomarker of Anthracycline Cardiac ToxicityR01HL163172 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Aarti Asnani · 2022 to 2026
$3.2MGeneration of tumor specific immunity in canine osteosarcoma through dendritic cell hyperactivationU01CA272268 · NCI · TUFTS UNIVERSITY BOSTON · PI Cheryl A London, Jillian M Richmond · 2022 to 2026
$3.2MMechanisms of T cell activation in cardiac fibrosis and non-ischemic heart failureR01HL144477 · NHLBI · TUFTS UNIVERSITY BOSTON · PI ALCAIDE ALONSO, MARIA PILAR · 2019 to 2023
$3.2MEnhancing the efficacy of immunotherapy in DLBCL using rational combination approachesU01CA224153 · NCI · TUFTS UNIVERSITY BOSTON · PI LONDON, CHERYL A · 2017 to 2021
$3.1MCredentialing a Cross-Species Platform to Investigate Cancer Therapy-Associated Cardiovascular ToxicityR01CA243542 · NCI · TUFTS MEDICAL CENTER · PI JAFFE, IRIS Z, LONDON, CHERYL A · 2019 to 2023
$3.1MRegulation of T cell immune response in Heart Failure with Preserved Ejection FractionR01HL165725 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Maria Pilar Alcaide Alonso · 2023 to 2026
$2.5MCYP1 Inhibition as a New Therapeutic Strategy for Doxorubicin CardiomyopathyK08HL145019 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ASNANI, AARTI · 2019 to 2023
$837kComparing the role of MyD88 and TRIF in T-cell effector function and the development of heart failureF30HL162200 · NHLBI · TUFTS UNIVERSITY BOSTON · PI Abraham Bayer · 2022 to 2026
$238kCharacterizing mechanisms of T cell-mediated cardiac pathology in Heart Failure with Preserved Ejection FractionF31HL159907 · NHLBI · TUFTS UNIVERSITY BOSTON · PI SMOLGOVSKY, SANDRA · 2022 to 2023
$67kAmerican Heart Association (American Heart Association, Inc.) 906361American Heart Association (American Heart Association, Inc.) 906561NCI NIH HHS R01 CA243542NCI NIH HHS U01 CA224153NCI NIH HHS U01 CA272268NHLBI NIH HHS F30 HL162200NHLBI NIH HHS F31 HL159907NHLBI NIH HHS K08 HL145019NHLBI NIH HHS R01 HL144477NHLBI NIH HHS R01 HL163172NHLBI NIH HHS R01 HL165725Tufts University Springboard Tier 1U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) NIH U01CA272268U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) 3R01HL144477-04S1U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL144477U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL159907AU.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL162200U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL165725U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) NIH K08 HL145019U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) NIH R01 HL163172
Abstract
Doxorubicin, the most prescribed chemotherapeutic drug, causes dose-dependent cardiotoxicity and heart failure. However, our understanding of the immune response elicited by doxorubicin is limited. Here we show that an aberrant CD8
Indexed as
Disease Models, AnimalDoxorubicinFibrosisInterferon-gammaT-Lymphocytes, CytotoxicAnimalsAntibiotics, AntineoplasticCardiomyopathiesCardiotoxicityCell AdhesionCell DegranulationCells, CulturedChemokine CXCL10Chemokine CXCL9DogsFemaleAntibiotics, AntineoplasticChemokine CXCL10Chemokine CXCL9CXCL10 protein, humanCXCR3 protein, humanDoxorubicinGranzymesGzmb protein, mouseIFNG protein, humanIFNG protein, mouseInterferon-gammaReceptors, CXCR3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.